Buscar
Ovid Therapeutics Inc
OVIDAñadir a la lista de seguimiento
2.220USD
-0.150-6.33%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
414.34MCap. mercado
PérdidaP/E TTM
Más Datos de Ovid Therapeutics Inc Compañía
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Información de Ovid Therapeutics Inc
Símbolo de cotizaciónOVID
Nombre de la empresaOvid Therapeutics Inc
Fecha de salida a bolsaMay 05, 2017
Director ejecutivoAlexander (Margaret A)
Número de empleados23
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 05
Dirección441 Ninth Avenue, 14Th Floor
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10001
Teléfono12127764381
Sitio Webhttps://ovidrx.com/
Símbolo de cotizaciónOVID
Fecha de salida a bolsaMay 05, 2017
Director ejecutivoAlexander (Margaret A)
Ejecutivos de Ovid Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
217.58K
+8.08%
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
8.79K
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Ms. Margaret (Meg) Alexander
Ms. Margaret (Meg) Alexander
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
217.58K
+8.08%
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
8.79K
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Ovid Therapeutics Inc?
Los cinco principales accionistas de Ovid Therapeutics Inc son: Dr. Stelios B. Papadopoulos, Ph.D.
¿Cuántas instituciones poseen acciones de Ovid Therapeutics Inc (OVID)?
A fecha de 2026Q1, 217 instituciones poseen acciones de Ovid Therapeutics Inc, con un valor de mercado combinado de aproximadamente 67.84M, lo que representa el 39.21% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 12807224.00.